Wells Fargo & Company Reiterates Equal Weight Rating for Affimed (NASDAQ:AFMD)

Wells Fargo & Company reissued their equal weight rating on shares of Affimed (NASDAQ:AFMD) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has a $0.10 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $11.00.

AFMD has been the topic of several other reports. StockNews.com started coverage on Affimed in a report on Sunday, May 11th. They issued a “sell” rating on the stock. Leerink Partners restated a “market perform” rating and set a $0.39 price target (down from $5.00) on shares of Affimed in a report on Tuesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Affimed has an average rating of “Hold” and an average price target of $7.90.

Affimed Stock Down 34.5%

Shares of AFMD stock opened at $0.09 on Tuesday. The business’s 50 day simple moving average is $0.75 and its 200 day simple moving average is $1.44. Affimed has a one year low of $0.07 and a one year high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Hedge Funds Weigh In On Affimed

A number of institutional investors and hedge funds have recently modified their holdings of AFMD. Jane Street Group LLC bought a new position in shares of Affimed during the 3rd quarter worth approximately $44,000. Intellectus Partners LLC raised its position in shares of Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 32,053 shares during the period. Finally, Northern Trust Corp acquired a new position in shares of Affimed during the fourth quarter worth approximately $218,000. 30.82% of the stock is currently owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.